Jiangsu Sihuan Bioengineering (stock code: 000518) as an enterprise specialized in pharmaceutical sales, has continuously demonstrated its stable operation under the overall environment of the pharmaceutical industry. Recently released Q1 report of 2024 reveals the latest financial situation and performance of the company for investors.
From the perspective of asset and liability data, the total assets of Jiangsu Sihuan Bioengineering at the end of the period reached CNY 653 million, slightly down compared to the beginning of the period, with a decrease of 1.13%, maintaining a stable level. The total liabilities amounted to CNY 144 million, with a similar downward trend, and the asset-liability ratio decreased from 22.42% at the beginning of the period to 22.03%, showing the company's good ability in controlling liabilities. The goodwill remained at zero, indicating that the company has not carried out large-scale M&A activities that may incur related risks.
In terms of profitability data, although the operating income of this reporting period slightly decreased by 1.08% compared to the same period of the previous year, the net income attributable to shareholders of the listed company achieved significant growth, reducing from a loss of CNY 189.6 million in the same period of the previous year to a loss of CNY 29.7 million in this period, with an increase of 84.35%. After deducting non-recurring gains and losses, the growth rate of net income reached 84.52%, indicating that the company's profitability of the main business has improved. At the same time, both basic EPS and diluted EPS also showed a positive growth trend.
Cash flow data is an important indicator for evaluating enterprise liquidity and operating efficiency. The net cash flow from operating activities of Jiangsu Sihuan Bioengineering in this reporting period was CNY 54.1 million, with a significant increase of 77.44% year-on-year, mainly due to the effective control and management of sales expenses during the reporting period. Although the net cash flow from investing activities showed a negative value, it was mainly due to the increase in the payment of fixed asset purchase and construction expenses compared to the same period of the previous year, which reflected the company's investment in expanding its scale and enhancing its strength from another perspective.
In summary, the Q1 report of Jiangsu Sihuan Bioengineering in 2024 shows that the company has achieved positive results in multiple aspects such as asset and liability management, profit improvement, and cash flow control. Despite the increasingly competitive environment in the pharmaceutical industry, Jiangsu Sihuan Bioengineering can still maintain a stable development pace and continuously enhance its core competitiveness. In the future, with the continuous development of the pharmaceutical industry and the further release of market demand, Jiangsu Sihuan Bioengineering is expected to achieve even more outstanding performance with its solid financial foundation and clear strategic planning.